Immtech Completes Malaria Prevention Trial
November 7th, 2007 by 
Barry - Admin BioPharmArena
Immtech Pharmaceuticals, Inc. (Amex: IMM) announced that it has completed its first malaria prevention (or “malaria challenge”) trial of pafuramidine, Immtech’s oral drug candidate. The exploratory study was designed to determine whether the Company should focus on commercializing a blood-stage or a liver-stage malaria prevention drug. The information obtained from this study is needed by Immtech in order to design the appropriate subsequent trials for pafuramidine’s registration to target malaria prevention, and by the Independent Ethics Committees and the regulatory agencies in order to review and approve subsequent studies for this indication.
Malaria prevention potentially represents a significant market opportunity for Immtech. Datamonitor estimates the market potential for a product with pafuramidine’s expected profile to exceed US $1.0 billion globally.
Posted in News, Clinical Research and Clincal Trials | 